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QUESTIONS AND ANSWERS ABOUT TOLBUTAMIDE, 
THE ORAL HYPOGLYCEMIC AGENT 
F R E D W . W H I T E H O U S E , M . D . ' A N D J O H N B . B R Y A N , M . D . * 
When insulin was found to be ineffective by mouih . attention was given to the 
deyelopmenl of an orally etfective hypoglycemic agent. Manv compounds have heen 
lesled over the years. Mosl have been too toxic for clinical use. 
Janbon in 1S)42 first described the hvpoghcemic action of sulfonamide compounds,' 
Recenlly. modif ied preparations have been siudied intensively in Germany and Ihe 
United .States. Onc preparalion. carbutamide. proved lo be loo toxic for general clinical 
use. Tolbu tamide^ a closely related cunipound. has proven to be relatively safe and 
has been made available throughout this country for Ihe ireatmeni of diabetes mellitus. 
This report summarizes our experience with Ihis agent and allempis to c lar i fy 
quesiions thai have arisen with ils use. Recent reporls a f f o r d Ihe interested reader 
.1 more detailed analysis of ils pharmacology and clinical use and an excellenl 
bibliography. 
Queslion: What is tolbutamide? 
Answer: I l is a sullonykirca conipound Ihal has a significani hvpoglycemic aclion 
when taken b\ mouth. 
Queslion: Ho« ' does lolbutamide acl? 
,\nsuer; ( urrenl opinions suggesi mulliphasic activity. Insulin musl be present 
lor an ef lec l . Fxperimcnlal evidence indicates thi;I lolbutamide I I 1 causes cither a pro-
diiciion of or a release of insulin f r o m ibe beta cells of the pancreas. (2 ) inhibils anti-
insulin faclors (insulinase) in the liver. iS ) slows ihe release of glucose f r o m the liver, 
lo lbui . imide has no effeci on olher endocrine organs nor does it increase glucose 
uptake b\ the individual cell. Ils action is not inhibiled by ablalion of the pi tui tar \ , 
i l u i i u d or adrenal glands. There is no toxic effeci on the alpha cells of ihe pancreas. 
It must be emphasi/ed that the linal and possibh correcl modus operandi of tolbutamide 
li.i-^ no! \e l been esl.iblished. 
Question: Is Ihere a h\pogl\cemic effeci in all diabetics as is true wi th insulin? 
.Answer: No, Animals fo l lowing lotal pancreatectomy or alloxanizalion show 
no h\pogIycemic effeci . In humans the percenlage of patients wi th a significani 
h\poghcemic effect closely parallels the percenlage of patients wi lh insulin extractable 
f r o m the pancreas. Those palienis without extractable insulin do noi respond lo 
tolbutamide. 
Queslion: Is tolbutamide effecliye in diabeiic acidosis? 
.Answer: No Neither is i l effeclive in other acule complicalions of diabetes, 
inc'udint; inleclions and surgical stress. 
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Question: What arc the indications and conlra-indications for ils use? 
Answer: Table 1 indicates our curreni opinion based on over a year's clinical 
i^ xpericnce. These indications are generallv irue, allhough there may be exceptions, 
rhey are lo be used as a guide when applied to the individual patient. 
Indications Contra-ind icat ions 
Diabetes less than 10 years' duration. Diabetes over 10 years' duralion, 
( Inset of diabetes over age 40. Onsel under age 40. 
•.dull type diabetes. Juvenile type diabetes. 
Diabetes controlled with /ov ihan 30 uniis of Diabetes controlled wilh imuf than 30 unils of 
insulin daily. insulin daily. 
I oupcraiive palienl. Uncooperative paticni. 
Acute complications. 
(Cetosis. 
Ihe presence of one conlra-indicalion is sufficient lo disqualify a palienl for 
i 'Ihutamide Iherapy. Tolbutamide is an insulin subsiiuite clinically. Il is not indicated 
in the obese diabeiic palient before an adequate trial wilh undernutrition has been 
.ecomplished. Onlv if weight loss does not occur, or if not successful in conlrollini^ 
Ihe diabetes, should lolbuUimide be consideretl. 
Queslion: Whal are the side-effects of tolbutamide? 
Answer: We have seen one case of dermalilis and one case of nauseii and 
omiling, requiring cessation of the drug, in l.'^ O cases treated with lolbutamide. There 
may be transient leukopenia, but no olher hemalologic complications have been en-
countered. Crystalluria does not occur. We have exjierienced no hepatic dysfunction. 
("t'Donovan' reporls three perceni side-effects in over 70[)il clinic:il cases. These have 
all been mild. There are no known dealhs diicctlv allribulable to lolbutamide. 
Queslion: How is a patieni regulaled wiih tolbutamide? 
Answer: Once a decision to use tolbutamide is made, inilialion may be accom-
plished either in the hospital or with frequent office visits. Hospitalizalion is recom-
mended if there is any queslion regarding lhc palienl's likelihood of response. The 
following program has been generally adopled in our clinic: 
1. Begin wiih I gram 3 times daily. 
2. After 1-3 days, decrease to 1 gram twice daily. 
3. Adjust the dailv maintenance dosage with the help of frequent urine lesls 
and blood tests for" sugar. 
4. If the patieni is on insulin al the lime of initiation, 
a. omit insulin if less than 20 unils per day. 
b. If over 20 units daily, decrease Ihe daily dose 25-50 perceni initially, and 
then eliminate ihe insulin if Ihe blood sugars so indicale. 
5. Check the white blood count Irequenlly al the beginning of therapy. 
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Question, How long should one await a successful response? 
Answer: Not longer than 7-10 days. If the degree of diabetic control deteriorates 
sooner, abandon the trial at once and start insulin, The development of ketonuria 
indicates failure. It is imperative thai the patieni be kept under close observation 
during Ihis trial period. 
Queslion: Whal is the average maintenance dose? 
Answer: Table 2 records the maintenance dosage of 83 patients regulaled on 
lolbulamide. 
Table 2 
Maintenance Dosage of Tolbutamide 






Question: Can tolbutamide and insulin be used logelher? 
Answer: Yes, but there is little point in it. The only advantage of lolbulamide 
over insulin is its effectiveness hy mouth. Theoretically, one might lower a very large 
daily dose of insulin to a more convenient level wilh the aid of lolbutamide. We have 
tried this twice wiihout success. 
Question: Should lolbulamide he used in the obese diahetic patieni? 
Answer; Tolbutamide, like insulin, is contra-indicated initially in the obese 
diabeiic patieni. Undernutrition should be tried first. If optimum weight is accom-
plished and still the diabetes is not controlled, then tolbutamide may be tried. If poor 
cooperalion prevents weight loss, then lolbutamide probably should also be avoided. 
Queslion: Can the diet be liberalized when lolbulamide is used? 
Answer: No, If anything, it should be followed more closely. 
Queslion: Once on tolbutamide, must the palienl stay on it? 
Answer: Like insulin, no. A patient wilh mild diabetes and good control may 
improve his glucose tolerance lo the degree lhat diet alone will adequately control 
his diabetes. 
Question: If the patieni is regulated on tolbutamide, will insulin again be necessary? 
Answer: Most patients on lolbulamide will require insulin if acute stress occurs. 
A few patients well regulated on tolbutamide at the beginning will gradually lose this 
cood control. They must restart insulin. 
Queslion: How is tolbutamide supplied? 
Answer: Half-gram tablets, hollies of 50. S6.75 per bottle, filled by prescription 
only. 
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Queslion: Docs lolbutamide have any antibacterial activity? 
Answer: No. 
Question: Has hypoglycemia been a problem? 
Answer: No, Wc have seen no serious hypoglycemic reactions. There have been 
several mild reactions occurring during the first few days following initiation of 
i.ilbutamide therapy. 
Question: Whal have been the failures? 
Answer: Our failures with the use of lolbulamide include patients wilh diabetes 
LUid carcinoma of ihe pancreas (4 cases), sieroid diabetes ( I case) and juvenile type 
diabetes. The basic nature of tbc diabetes appears lo be the most importani determinanl 
III the individual response to tolbutamide. 
Queslion: What theoretical danger exists wilh the use of lolbulamide? 
Answer: Permanent diabetes can be produced in animals by chronic overstimula-
lion of the beta cells of the pancreas. Tolbutamide is a beta cell stimulator. Will 
lolbulamide in time produce "total" diabetes in patients mainlained on il? 
A palient with diabetes well regulaled with lolbutamide will lose this sensitivity 
in the presence of acule complicalions. This may make ihe palient more vulnerable 
lo the rapid occurrence of ketosis and acidosis Ihan a similar patient regulaled with 
insulin. 
Summary: 
The experience at the Henry Ford Hospital with tolbutamide is reviewed. Perlinenl 
questions regarding ils use are answered. The only advantage of tolbutamide over 
insulin is onc of convenience — il is effective orally. The present and future heallh 
of the diabetic must not be compromised for mere convenience. Thc patients using 
tolbutamide musl be carefully and thoughlfully selected. 
We are grateful lo Doctor C. J. O'Donovan of the Upjohn Company, Kalam.izoo, for the 
generous supply of lolbulamide. 
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